Chimerix (NASDAQ:CMRX) Releases Earnings Results, Beats Estimates By $0.01 EPS

Chimerix (NASDAQ:CMRX) issued its earnings results on Friday. The biopharmaceutical company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01, Zacks reports. The company had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.31 million.

Chimerix Stock Up 0.4 %

Shares of NASDAQ CMRX traded up $0.04 during trading on Friday, hitting $8.51. The company had a trading volume of 1,508,704 shares, compared to its average volume of 2,084,137. The stock has a fifty day simple moving average of $5.24 and a two-hundred day simple moving average of $2.77. Chimerix has a fifty-two week low of $0.75 and a fifty-two week high of $8.52. The firm has a market capitalization of $764.91 million, a price-to-earnings ratio of -9.05 and a beta of 0.32.

Analyst Ratings Changes

CMRX has been the topic of a number of recent research reports. Jefferies Financial Group reiterated a “hold” rating and set a $8.50 price objective (down from $10.00) on shares of Chimerix in a research note on Wednesday, March 5th. HC Wainwright restated a “neutral” rating and issued a $8.55 target price (down from $11.00) on shares of Chimerix in a research note on Wednesday, March 5th. StockNews.com began coverage on shares of Chimerix in a research note on Saturday, March 15th. They issued a “hold” rating for the company. Finally, Wedbush restated a “neutral” rating and issued a $8.55 target price (up from $7.00) on shares of Chimerix in a research note on Wednesday, March 5th.

Insider Activity

In related news, CEO Michael T. Andriole sold 7,370 shares of the business’s stock in a transaction dated Thursday, February 13th. The shares were sold at an average price of $4.52, for a total transaction of $33,312.40. Following the transaction, the chief executive officer now directly owns 609,603 shares in the company, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Insiders have sold a total of 20,760 shares of company stock worth $91,175 over the last 90 days. 13.10% of the stock is currently owned by company insiders.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.